Market analysts have identified strong momentum in the pharmaceutical sector with specific buy recommendations. Ajit Mishra, SVP of Research at Religare Broking, recommended a buy on Aurobindo Pharma at the current market price of ₹1,512 for a target of ₹1,595, advising traders to protect the position with a stop loss at ₹1,470. Additionally, Deven Mehata, Manager – Technical & Derivatives Analyst at IDBI Capital Market and Securities Ltd, identified a buying opportunity in the specialty pharma space with OneSource Specialty Pharma recommended at ₹1,834 for an upside target of ₹2,010, while protecting the position with a stop loss at ₹1,740. The biotechnology sector specifically focuses on companies developing innovative solutions like discovering new drugs, gene therapy, and creating advanced diagnostic tools.
Technical analysts have highlighted opportunities in the agrochemical and industrial manufacturing sectors. VLA Ambala, SEBI RA & Founder at SMT Stock Market, recommended an entry on Sumitomo Chemical India in the range of ₹435 to ₹445 for upside targets of ₹480 and ₹530, advising traders to maintain a stop loss at ₹400. In the industrial manufacturing space, Gaurav Sharma of Globe Capital highlighted momentum with a buy call on Graphite India at the current market price of ₹775 for an upside target of ₹840, advising traders to keep a strict stop loss at ₹750.
Telecommunications sector analysis shows positive price action with specific buy recommendations. Gaurav Sharma, Associate VP & HOR at Globe Capital, sees positive price action in the telecommunications major with Tata Communications recommended at the current market price of ₹1,652 for a target price of ₹1,850, suggesting a stop loss at ₹1,600 to manage downside risk. These recommendations span across multiple sectors including pharmaceuticals, agrochemicals, telecommunications, and industrial manufacturing, indicating broad market opportunities identified by brokerage firms and analysts.
The biotechnology sector represents companies involved in research, development, and production of biotechnology products, including drugs, vaccines, diagnostics, and agricultural products. As of May 11, 2026, Biocon Limited stands as the biggest biotech company in India by market capitalisation, focusing on biopharmaceuticals including biosimilars and research in diabetes, oncology, and immunology. The Indian biotechnology industry has demonstrated remarkable growth, increasing from $10 billion in 2014 to around $165.7 billion in 2024, with an annual growth rate of 17.9%. Looking ahead, the sector is expected to reach $300 billion by 2030, driven by advances in biomanufacturing, sustainability efforts, and innovation. The sector benefits from rising healthcare demand, government support for biotech manufacturing, increasing R&D activity, and growth in global healthcare markets.
